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Objective:We sought to prospectively determine the feasibility and safety of hyperthermic intraoperative intra-
cavitary cisplatin perfusion immediately after extrapleural pneumonectomy in the treatment of malignant pleural
mesothelioma.
Methods: Patients with malignant pleural mesothelioma who were surgical candidates underwent extrapleural
pneumonectomy followed by hyperthermic intraoperative intracavitary cisplatin perfusion, consisting of
a 1-hour lavage of the chest and abdomen with cisplatin (42C) at 225 mg/m2. Pharmacologic cytoprotection
consisted of intravenous sodium thiosulfate with or without amifostine. Morbidity and mortality were recorded
prospectively.
Results:Ninety-six (79%) of 121 enrolled patients underwent extrapleural pneumonectomy, of whom 92 (76%)
received hyperthermic intraoperative intracavitary cisplatin perfusion after extrapleural pneumonectomy. Fifty-
three (58%) patients had epithelial tumors, and 39 (42%) had nonepithelial histology. Hospital mortality was
4.3%. Morbidity (grade 3 or 4, 49%) included atrial fibrillation in 22 (23.9%) patients, venous thrombosis in
12 (13%) patients, and laryngeal nerve dysfunction in 10 (11%) patients. Nine patients had renal toxicity, which
was attributable to cisplatin in 8 of them. Among the 27 patients who also received amifostine (910 mg/m2),
1 patient had grade 3 renal toxicity attributable to cisplatin. Recurrence of malignant pleural mesothelioma
was documented in 47 (51%) patients, with ipsilateral recurrence in 17.4% of patients. The median survival
of the 121 enrolled patients was 12.8 months.
Conclusions: Hyperthermic intraoperative intracavitary cisplatin perfusion following extrapleural pneumonec-
tomy can be performed with acceptable morbidity and mortality. The use of amifostine in addition to sodium thio-
sulfate might reduce cisplatin-associated renal toxicity. Hyperthermic intraoperative intracavitary cisplatin
perfusion following extrapleural pneumonectomy might enhance local control in the chest.Malignant pleural mesothelioma (MPM) is a rare thoracic
cancer that originates in pleural mesothelial cells and prog-
resses relentlessly to encase the lungs and mediastinum,1
ultimately causing death by locoregional extension. This
malignancy is usually associated with previous asbestos ex-
posure2 and is refractory to standard treatment modalities,
including chemotherapy and radiation therapy. As a conse-
quence, patients with MPM usually have a poor prognosis,
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death is in the range of 7 to 12 months.3
Multimodality therapy, which includes maximal cytore-
ductive surgery4 followed by radiotherapy for local control
and chemotherapy for both locoregional and systemic con-
trol, has resulted in prolonged survival in selected patients
who have relatively early disease and adequate cardiopul-
monary function. The surgical treatment of MPM was
initially limited by unacceptable morbidity and mortality
for complete resection.5,6 The most effective surgical
approach for resection of macroscopic disease is extrapleural
pneumonectomy (EPP).7-9 Patients who are not candidates
for EPP as a result of insufficient cardiopulmonary reserve,
advanced age, or disease distribution might be candidates
for cytoreduction with pleurectomy/decortication (P/D).10
During the past 2 decades, the safety of these 2 effective
cytoreductive procedures was established in several centers
of expertise worldwide, providing surgeons with the ability
to achieve macroscopic complete resection (MCR)4 with
acceptable morbidity and mortality. In combination with aardiovascular Surgery c Volume 138, Number 2 405
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SAbbreviations and Acronyms
BWH ¼ Brigham and Women’s Hospital
EPP ¼ extrapleural pneumonectomy
HIOC ¼ hyperthermic intraoperative chemotherapy
IMRT ¼ intensity-modulated radiation therapy
MCR ¼ macroscopic complete resection
MPM ¼ malignant pleural mesothelioma
MTD ¼ maximal tolerated dose
P/D ¼ pleurectomy/decortication
POD ¼ postoperative day
variety of adjuvant therapies, primary surgical intervention
has led to multiple reports of prolonged disease-free interval
and survival relative to historical and contemporary
single-modality treatment strategies.11-13 Despite these ad-
vances, however, most patients experience eventual recur-
rence of their mesothelioma and death.
MPM exhibits a progression pattern characterized by
a tendency to recur locally. One study examining the pat-
terns of recurrence showed that 54% of the 25 patients
who had recurrence after trimodality therapy, the predomi-
nant site of first failure was within the ipsilateral hemithorax
(67% of all recurrences) followed by the abdomen (50%).14
The mechanism of this recurrence pattern might be regrowth
of microscopic residual or shed tumor cells or a second pri-
mary disease arising in the peritoneum or on the pleural sur-
face. The local nature of disease recurrence has emphasized
the need for improved locoregional control, and trials of
intraoperative radiation15 and photodynamic therapy16
have been undertaken. Potential shortfalls of these strate-
gies, however, include the inability to treat intra-abdominal
or peritoneal sites of disease.
We therefore investigated hyperthermic intraoperative
chemotherapy (HIOC) lavage as a means of delivering
high-dose regional therapy simultaneously to the 2 body
cavities at highest risk for recurrence with the objective of
sterilizing the microscopic surgical margins. Phase I studies
with bicavitary (thorax and abdomen) cisplatin perfusion
after EPP9,17 or P/D10 have been reported. These initial stud-
ies established a maximal tolerated dose (MTD) for cis-
platin, confirmed its safety, and suggested the efficacy of
the treatment in terms of improved time to disease progres-
sion and survival. In the present prospective phase II trial,
we sought to determine the feasibility and associated mortal-
ity and morbidity of administering HIOC at the established
MTD in a consecutive series of patients undergoing EPP.
MATERIALS AND METHODS
Objectives
The primary objectives of this study were to determine the feasibility of
HIOC with cisplatin immediately after EPP and to document the morbidity
and mortality of this treatment with particular reference to renal function.406 The Journal of Thoracic and Cardiovascular SuThe treatment protocol consisted of EPP followed immediately by intratho-
racic/intraperitoneal cisplatin HIOC at a dose of 225 mg/m2, with cytopro-
tection (mainly to prevent nephrotoxicity) using intravenous sodium
thiosulfate with or without intravenous amifostine.18 The secondary
objectives were to evaluate the pattern and timing of disease recurrence
and patient survival.
Eligibility and Enrollment
This prospective phase II protocol was approved by the institutional
review board. Patients with biopsy-proved MPM who were candidates for
EPP19 were offered participation in this study, and informed consent was
obtained from the patients. Study-specific inclusion criteria included the fol-
lowing: pathologic diagnosis confirmed by the institutional mesothelioma
pathology review panel, absence of radiographic evidence of metastatic dis-
ease, adequate cardiopulmonary function (ie, ejection fraction >45%,
absence of severe cardiac valvular abnormalities, absence of pulmonary
hypertension determined by using echocardiographic analysis, and preoper-
ative FEV1 of 2 L and predicted postoperative FEV1 of>0.8 L based on
a quantitative ventilation-perfusion scan), adequate renal function (ie, serum
creatinine level of<1.5 mg/dL and estimated creatinine clearance of>45
mL/min), adequate hepatic function (aspartate aminotransferase level of
<80 IU/L and total bilirubin level of<1.9 mg/dL), normal contralateral pul-
monary function, and Karnofsky performance status of 70 or greater. Exclu-
sion criteria included the following: previous chemotherapy, radiation
therapy, or both for mesothelioma; any chemotherapy, radiation therapy,
or both administered within 3 years for another malignancy; prior malig-
nancy with remission for less than 3 years; pregnancy at the time of the
operation; or any severe nonmalignant comorbid disease.
Surgical Intervention and Intraoperative
Hyperthermic Lavage
EPP was attempted for all enrolled patients. This operation consists of en
bloc resection of the visceral, parietal, and mediastinal pleurae; the lung; the
ipsilateral diaphragm; and the portion of the pericardium that borders the
ipsilateral lung, as previously described.19 The pericardial and hemidiaph-
ragmatic defects are reconstructed with a polytetrafluoroethylene patch
(Gore-Tex patch; W. L. Gore & Associates, Flagstaff, Ariz). Patients in
whom MCR (<1.0 cm3 tumor) could not be achieved were considered
unresectable.
After extirpation of the entire specimen, careful attention was directed
toward complete hemostasis of the surgical field. Intracavitary lavage of
the ipsilateral chest and abdominal cavities was carried out for 60 minutes
with a solution of 225 mg/m2 cisplatin in dialysate (Baxter, Deerfield, Ill)
maintained at 42C, as previously described.10 Intravenous sodium thio-
sulfate for renal protection (4 g/m2 bolus in 250 mL of sterile water over
10 minutes) was administered immediately after the cisplatin lavage was
concluded. This was followed by an additional infusion of 12 g/m2 so-
dium thiosulfate in 250 mL of sterile water over 6 hours. Eighty-two of
92 patients received a second identical infusion of sodium thiosulfate.20
After interim analysis of renal toxicity in 65 patients showing that 7
had grade 4 renal toxicity, the protocol was amended, and 27 patients
also received amifostine for additional renal protection. The infusion of
910 mg/m2 amifostine (Ethyol; Alza Pharmaceuticals, Mountain View,
Calif) was administered intravenously over 15 minutes, starting 30 min-
utes before cisplatin perfusion and 90 minutes before sodium thiosulfate
administration.21
The temperature of the perfusate was monitored continuously with intra-
thoracic and intra-abdominal probes, and the body temperature was moni-
tored with an esophageal probe. Furosemide, low-dose dopamine,
mannitol, and/or intravenous fluids were used to maintain urine output at
greater than 100 mL/h for the duration of the lavage and for 1 hour after
its completion. Patients were maintained on positive pressure ventilation
for 24 hours postoperatively to maximize lung expansion.rgery c August 2009
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After the operation, complete blood counts and chemistry panels were
monitored daily until discharge. Adverse events that occurred during post-
operative hospitalization were graded according to Common Terminology
Criteria for Adverse Events version 3.0 (https://webapps.ctep.nci.nih.gov/
webobjs/ctc/webhelp/welcome_to_ctcae.htm). After discharge, patients
were seen and evaluated by a physician in ambulatory follow-up at 1 to 2
weeks, 6 to 8 weeks, and then 4-month intervals. A computed tomographic
scan of the chest was obtained at the second follow-up and every 4 months
thereafter to monitor for evidence of recurrence. Date of recurrence was con-
sidered to be the date of the first radiographic study during which recurrence
was demonstrable. Mortality was considered to be disease related. Adjuvant
therapy was neither mandated nor prohibited by the protocol, and most of
the patients were treated outside the Boston area. Therefore data regarding
adjuvant therapy were not collected and are not reported herein.
Statistical Analysis
Morbidity was defined as any adverse event occurring during the post-
operative hospitalization. Mortality was defined as any death during the
initial postoperative hospitalization or within 30 days of the operation.
Pathologic staging was assigned for all cases by using American Joint
Committee on Cancer and Brigham and Women’s Hospital (BWH) crite-
ria.22 Overall survival was estimated by using the Kaplan–Meier method,
and the log-rank test was used to compare differences between patient sub-
groups. Cancer-specific survival was based on the cumulative incidence es-
timate, with death associated with intensity-modulated radiation therapy
(IMRT; 8 patients) considered as a competing risk.23 The Gray test was
used to compare the cancer-specific survival difference between patient
subgroups.24 The analysis of overall survival was computed with SAS ver-
sion 9.1 (SAS Institute, Inc, Cary, NC) statistical software, whereas the
competing-risks analysis was performed with the cmprsk software package
in R version 2.5.1. Contingency data analysis was conducted by using the
Fisher’s exact test. The sample size was chosen to provide the 85% statis-
tical power needed to determine whether the addition of HIOC is associ-
ated with an improvement in overall survival compared with that seen in
historical control subjects who underwent EPP without HIOC at our insti-
tution. The goal was to detect a hazard ratio of 0.714 at a 1-sided signifi-
cance level of 10%, which is similar to the survival gain observed among
the P/D cohort that underwent HIOC.25 One hundred twenty-one patients
were enrolled to ensure an effective sample size of at least 85 evaluable
patients who actually completed HIOC. The patient numbers also provided
adequate precision for the estimation of mortality, morbidity, and toxicity.
Although a priori hypotheses were not planned for the secondary end
points, the study design included an early stopping rule for unacceptable
mortality.
RESULTS
Enrollment and Treatment
One hundred twenty-one patients were enrolled in the
study over a 21/2 -year period (January 2004 to June 2006).
The study cohort was generally representative of patients
with MPM presenting for surgical therapy in terms of demo-
graphic and histologic characteristics but included a rela-
tively high percentage of patients with stage III disease or
greater (Table 1). Twenty-five patients had tumors that
were not resectable by means of EPP because of invasion
into the chest wall (n ¼ 21), invasion into major central
blood vessels (n¼ 3), or diffuse abdominal metastases noted
at the time of the operation (n ¼ 1). Of the patients whose
tumors were deemed unresectable by means of EPP, 14The Journal of Thoracic andunderwent partial tumor debulking, and no resection was
attempted for the remaining 11 patients.
The majority of the patients (96 [79%]) were found to
have resectable tumors and underwent EPP. Of these, 92
patients completed HIOC treatment according to the
protocol. Four patients did not complete HIOC treatment
because of hemodynamic instability (n ¼ 3) or technical
failure of the perfusion system (n ¼ 1). These patients
were excluded from the study, yielding a study cohort of
92 patients.
Morbidity and Mortality
Mortality. Four of the 92 treated patients died (mortality,
4.3%). One patient died within 30 days of the operation
from multiorgan failure after cardiopulmonary arrest (post-
operative day [POD] 24). Three additional patients died dur-
ing the postoperative hospitalization period (multiorgan
TABLE 1. Overview of enrolled patients treated by using EPP with
HIOC
Patients enrolled No. Percentage of 121
General
Enrolled 121
Resected 96 79
Treated 92 76
Partial resection or P/D 14 12
Unresectable 11 9
EPP with no HIOC 4 3
Patients treated Percentage of 92
Sex
Male 73 79
Female 19 21
Age (y)
Median (range) 60 (27-78)
Laterality
Right side 42 46
Left side 50 54
Tumor histology
Epithelial 53 58
Biphasic 36 39
Sarcomatoid 3 3
AJCC staging
I 2 2
II 12 13
III 50 54
IV 28 30
BWH staging
I 6 7
II 28 30
III 58 63
Hospital stay Median (range) 12 (7-160)
EPP, Extrapleural pneumonectomy; HIOC, hyperthermic intraoperative chemother-
apy; P/D, pleurectomy/decortication; AJCC, American Joint Committee on Cancer;
BWH, Brigham and Women’s Hospital.Cardiovascular Surgery c Volume 138, Number 2 407
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53, and sepsis after patch dehiscence at POD 160).
Morbidity. Forty-five patients had postoperative complica-
tions (48.9% morbidity, Table 2). The most common com-
plication was atrial arrhythmia (22 [24%] patients). Grade 3
to 4 renal toxicity occurred in 9 patients, manifesting as in-
creased serum creatinine values (9 [9.8%] patients) and re-
nal failure (3 [3%] patients). The 3 patients who experienced
renal failure required dialysis, one for 3 weeks, one for 6
weeks, and one for 7 months. One patient had renal failure
attributable to sepsis and multiorgan failure after a perioper-
ative cardiopulmonary arrest. Renal toxicity among the re-
maining 8 (9%) patients was attributed to cisplatin. Seven
of 65 patients treated with sodium thiosulfate alone experi-
enced cisplatin-related renal toxicity compared with only
1 of 27 patients treated with amifostine and sodium thiosul-
fate (P ¼ .429, Table 3).
Recurrence. Radiographic or pathologically confirmed
recurrence of MPM was observed in 47 (51.1%) patients.
The most common sites of recurrence were the contralateral
hemithorax (61.7% of all recurrences, 29 [31.5%] treated
patients), abdomen (51.1% of all recurrences, 24 [26.1%]
treated patients), ipsilateral hemithorax (34.0% of all recur-
rences, 16 [17.4%] treated patients), and distant regions
(8.5% of all recurrences, 4 [4.35%] treated patients). Two
(3.5%) of 47 evaluable patients had recurrences only in
the ipsilateral hemithorax. The median estimated disease-
free interval for all 92 patients was 15.3 months. Estimated
median survival from time of recurrence to death for the
47 patients was 3.1 months.
TABLE 2. Grade 3 and 4 adverse events
Grade
3
Grade
4
Total
patients
Percentage
of 92
Adverse event
AF 17 5 22 23.9
Major morbidity (non-AF)
Thrombosis/thrombus/embolism 8 4 12 13.0
Laryngeal nerve dysfunction 10 10 10.9
ARDS/respiratory failure 1 5 6 6.5
Cardiac ischemia or CP arrest 3 2 5 5.4
Chylothorax 4 4 4.3
Increased creatinine 6 3 9 9.8
Renal failure 3 3 3.3
Pneumonia 3 3 3.3
Fistula, bronchus 2 1 3 3.3
Empyema 1 1 2 2.2
Ileus 2 2 2.2
Intraoperative injury, carotid
artery
1 1 1.1
Fistula, enteric 1 1 1.1
Intraoperative injury, spleen 1 1 1.1
AF, Atrial fibrillation; ARDS, acute respiratory distress syndrome; CP, cardiopulmo-
nary.408 The Journal of Thoracic and Cardiovascular SurSurvival. At the time of this analysis, 20 of the 92 treated
patients were known to be alive, with a median follow-
up of 31.2 months (range, 16.7–45.8 months). Of the
20 patients who are alive, 15 are without recurrence, and
5 have evidence of recurrence. No patients died of renal
toxicity. Forty-five of 92 treated patients died of known
recurrence.
Overall median survival of the 121 patients enrolled in
this study was 12.8 months. Median survival of the treatment
cohort (92 patients) was 13.1 months versus 11.0 months for
patients who did not undergo the protocol-specified treat-
ment (n ¼ 29, P ¼ .0133, Figure 1). Patients with epithelial
histology (n¼ 53) had a longer overall median survival time
(17.1 months) compared with patients with the sarcomatoid/
biphasic cell type (n ¼ 39, 10.9 months, P ¼ .007). Early-
stage disease (BWH stage I or II, n ¼ 58) was associated
with longer median survival times (21.3 months) than ad-
vanced-stage disease (BWH stage III; n ¼ 34, 11.5 months;
P ¼ .0071). There were no significant differences between
tumor site, sex, or age (Figure 1). According to our analysis,
patients with stage III disease had nearly half the survival
of patients with stage I and II disease (21.3 vs 11.5 months,
P ¼ .0071). This is also less than the overall survival of the
treatment cohort (13.1 months, statistical comparison not
done). Overall cancer-specific survival was 16.9 months
for the treatment cohort (n ¼ 92).
DISCUSSION
This prospective phase II study establishes the safety and
feasibility of administering HIOC after EPP. Of 121 pa-
tients, 96 underwent EPP (79% resectability). Ninety-two
of those patients underwent HIOC after EPP. Postoperative
mortality was 4.3%. These rates are similar to those previ-
ously reported in other EPP series, which report postopera-
tive mortalities between 3.2% and 7%.7,8,25,26 Forty-five
(48.9%) of 92 patients experienced either grade 3 or 4 tox-
icity, which is similar to previous reports.7,11 Atrial fibrilla-
tion and respiratory adverse events have been previously
described as common complications after EPP and occurred
at the expected rates. Grade 3 or 4 renal toxicity occurred in
9 (9.8%) patients.
Despite careful screening and perioperative management,
renal toxicity attributable to HIOC with cisplatin remains
a concern for a small subset of patients. Comparison of the
amifostine and sodium thiosulfate group with the sodium
thiosulfate–only group suggested a qualitative reduction in
the incidence and severity of renal toxicity in the group
TABLE 3. Distribution of cisplatin-related renal toxicity in patients
treated with and without amifostine (P ¼ .429)
Renal toxicity No renal toxicity
With amifostine (n ¼ 27) 1 26
Without amifostine (n ¼ 65) 7 58gery c August 2009
Tilleman et al General Thoracic SurgeryTreatment Cell type
BWH Stage AJCC Stage
0 10 20 30 40 50 0 10 20 30 40 50
0 10 20 30 40 500 10 20 30 40 50
0.75
0.50
0.25
0.00
1.00
0.75
0.50
0.25
0.00
1.00
0.75
0.50
0.25
0.00
1.00
0.75
0.50
0.25
0.00
1.00
Treatment N Median
BWH I & II
BWH III
21.334
11.558
Resectable
Unresectable
13.192
11.029
p=0.01 33
Treated 
Untreated 
Type N Median
Epithelial 53 17.1
Non -Epithelial 
Nonepithelial 10.9
Epithelial
N Median
P=0.0071
BWH I & II
BWH III 
StageStage N Median
14 32.4
78 12.7
p=0.01 00
AJCC I & II 
AJCC III & IV
AJCC I & II 
AJCC III & IV
39
p=0.0007
A
D
B
C
FIGURE 1. Kaplan–Meier survival estimates for all enrolled patients (A) and patients undergoing extrapleural pneumonectomy and hyperthermic intrao-
perative intracavitary cisplatin lavage (B–C). A, Log-rank comparison demonstrated longer survival for resected patients versus patients whowere unresected/
untreated with HIOC. B, Significantly longer survival was demonstrated for patients with epithelial versus nonepithelial tumors. C and D, Pathologic tumor
staging by using Brigham and Women’s Hospital (BWH) staging and by using the American Joint Committee on Cancer (AJCC) staging system.G
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Sreceiving both cytoprotective drugs (1/27 compared with
7/65). Portions of this work have been presented in abstract
form.27 This finding was not statistically significant because
of the insufficient number of patients in these subgroups, but
given the encouraging reduction in renal toxicity when so-
dium thiosulfate alone (7/65) was replaced with sodium thio-
sulfate plus amifostine (1/27), we recommend both drugs for
renal protection during HIOC with cisplatin. An ongoing in-
vestigation is focused on further improvement in the early
detection and prevention of renal toxicity.
The median survival of 13.1 months in this treatment
cohort (92 patients) is encouraging, given that most had at
least stage III disease and nearly half had nonepithelial histol-
ogy. An exploratory analysis of patients who died of unantic-
ipated complications from HIOC in combination with IMRT
revealed a potential median survival of 16.9 months. On the
basis of this experience, we do not recommend IMRT in pa-
tients with mesothelioma until further research on the safety
of this modality can be performed. Patients not treated with
EPP received other treatments, including pleurectomy (n ¼
14) and chemotherapy (n¼ 15). Median survival for patients
who did not undergo the above protocol was 11 months.
The observed patterns of disease recurrence14 included
a low incidence of initial recurrence in the ipsilateral hemi-
thorax (34.0%) and a concomitant high incidence of recur-The Journal of Thoracic andrence in the contralateral hemithorax (67%) and abdomen
(50%), which remains a fatal problem for patients who
have undergone pneumonectomy and highlights the need
for improved systemic therapies for MPM once local control
has been achieved (Table 4).
In this phase II study the safety and feasibility of HIOC
after MCR by surgical intervention has been demonstrated
as a novel multimodality platform for MPM. Although the
increased local dose level of cisplatin permitted by regional
application would be expected to improve its efficacy, it
remains relatively inactive as a single agent.28-30 Response
rates for cisplatin alone were reported as 13.6% and
16.7%,29,30 and a 41.3% response rate was reported for
pemetrexed/cisplatin.30 Encouraged by the evidence that
combined chemotherapy with pemetrexed plus cisplatin
TABLE 4. Sites of pleural mesothelioma recurrence
Site No.
Recurrences (%),
Tilleman and
coworkers, 2009*
Recurrences (%),
Baldini and
coworkers, 199714
Ipsilateral hemithorax 16 34 67
Contralateral hemithorax 29 62 33
Abdomen 24 51 50
Distant 4 9 8
*Current article.Cardiovascular Surgery c Volume 138, Number 2 409
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Scompared with cisplatin alone for mesothelioma improves
survival,30 we are currently studying a combination regimen
using this alternative. A phase I trial of HIOC with cisplatin
at its established MTD in combination with dose-escalated
gemcitabine after EPP or P/D, as appropriate, is currently
open at our institution (http://www.clinicaltrials.gov/ct2/
results?term¼tilleman). We are using gemcitabine com-
bined with cisplatin rather than pemetrexed initially because
it has been safely provided as intracavitary therapy in the
abdomen for ovarian cancer.
The present prospective phase II study establishes that
HIOC after EPP can be performed with acceptable morbidity
and mortality compared with previous studies that report
similar numbers.7,25,26 Cytoprotection with amifostine and
sodium thiosulfate merits further investigation for control
of cisplatin-related renal toxicity.
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Discussion
Dr ValerieW. Rusch (New York, NY). Thank you for asking me
to discuss this excellent article, which was extremely well pre-
sented.
During the past 20 years, there have been significant improve-
ments in the management of this disease, including a better under-
standing of its biology, improved methods and staging, decreases in
operative mortality, and the development of better radiation and
chemotherapy treatments. However, MPM is still refractory to stan-
dard treatment approaches and is usually fatal. Therefore novel
approaches to the treatment of this disease are clearly needed,
and in this regard I congratulate your group for innovative work
testing the application of hyperthermic intracavitary chemotherapy
to patients undergoing resection for MPM.
Intracavitary chemotherapy in conjunction with maximal cytor-
eductive surgery has become a standard treatment option for peri-
toneal-based malignancies, such as metastatic ovarian cancer and
primary peritoneal mesothelioma. The mortality and morbidity of
this treatment strategy are clearly linked to the expertise of thergery c August 2009
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Ssurgical and anesthetic team because the operations are usually
long and associated with high need for intravenous fluids and trans-
fusions. Previous studies for peritoneal disease have shown that
nonplatinum chemotherapy regimens appear to be associated
with fewer serious adverse events, such as renal toxicity. Because
intracavitary chemotherapy in either the pleural or peritoneal cavi-
ties penetrates to a depth of only about 5 mm, successful treatment
with this modality depends on the amount of tumor remaining after
cytoreductive surgery. Moreover, multiple cycles of intraperitoneal
chemotherapy or the addition of systemic therapy appear to play
a role in achieving better long-term disease control.
Other studies have tested the application of intracavitary chemo-
therapy to malignant pleural effusions and to metastatic thymoma.
In the early 1990s at Sloan–Kettering, we performed a phase II trial
in patients with MPMwho received intrapleural cisplatin and mito-
mycin without hyperthermia immediately after pleurectomy and
decortication. Systemic chemotherapy was added postoperatively.
Briefly, this trial showed that intrapleural chemotherapy can be ad-
ministered safely by using standard measures of intensive hydration
without renal protective agents but that the treatment approach was
relatively ineffective in preventing local tumor recurrence. Impor-
tantly, pharmacokinetic studies from that trial showed that very
high chemotherapy drug levels can be achieved intrapleurally but
that systemic absorption was rapid, with peak plasma levels being
reached within 1 hour, emphasizing the importance of protecting
renal function when administering cisplatin intrapleurally.
The present study by the Brigham group and the 2 previous trials
that they performed extend this experience with intrapleural che-
motherapy in several ways: by adding hyperthermia, which is
thought to enhance chemotherapy activity; by adding sodium thio-
sulfate and amifostine as renal protective agents to enable the use of
very high-dose chemotherapy; and by perfusing both the pleural
and peritoneal cavities in the hope of decreasing the risk of perito-
neal, as well as pleural, disease recurrence.
As shown here, the combined modality treatment was feasible
with a 4% in-hospital mortality but was associated with significant
morbidity. In the manuscript draft that I received, there was an
overall 14% risk of significant renal dysfunction and a 13% risk
of deep venous thrombosis and pulmonary embolus, a problem
that has also been noted with intraperitoneal chemotherapy.
Unfortunately, the median survivals are very similar to those ob-
served in trials of other, simpler treatment strategies, such as resec-
tion and radiation, and appear less favorable than the median
survivals in recently reported European and North American trials
of induction systemic therapy followed by EPP and adjuvant hemi-
thoracic radiation. Moreover, recurrence in the ipsilateral thorax
and peritoneum with this approach remains quite frequent.
Therefore at this point, one could ask whether the treatment
strategy used in this trial is ready for export into more routine clin-
ical practice. I think the answer is no, given the substantial risk of
treatment-related morbidity and mortality and median survivals
that do not suggest superiority over other treatment regimens.The Journal of Thoracic andHowever, I hope that these provocative results will lead the Brig-
ham group and other investigators to additional trials that will
define the ultimate role of this approach in the treatment of this dif-
ficult disease. I would encourage them to consider pharmacoki-
netic studies that might identify ways to minimize renal toxicity.
In this regard I would like to ask you 3 questions.
First, does the reduction of operative mortality from 11% in the
first study reported by your group in the Journal of Clinical Oncol-
ogy in which patients underwent pleurectomy and decortication to
4% in this trial that used EPP merely reflect a 10-year difference in
the patients’ median age between those 2 studies, or is it related to
other factors?
Dr Tilleman. Dr Rusch, thank you very much for the summary
and the review comments.
There is a difference between those 2 studies, the one reported in
the Journal of Clinical Oncology and the one we are presenting
right now. The difference can be attributed to several things. One
of them is, as you pointed out, the difference in patient age (71 years
for the P/D strategy vs 60 years for the current EPP strategy).
I would like to emphasize that in the Journal of Clinical Oncology
we have reported P/D in patients who were not eligible for EPP
because of high risk; hence a higher mortality might be expected.
The last contribution might be due to an improvement in the peri-
operative critical care during the years, and there is a learning curve
here.
Dr Rusch. In a previous phase I trial you found that amifostine
did not provide adequate protection against renal toxicity. Can you
explain why it was added to thiosulfate in this study and why it
appears that it might work?
Dr Tilleman. You are correct, the phase I study in which we
applied only amifostine did not show significant renal protection;
however, in this study we have shown that thiosulfate and amifos-
tine administered together have created this change. In this study
there were 9 patients who had renal toxicities with thiosulfate,
and only a single patient had renal toxicity after the administration
of amifostine in addition to thiosulfate. Therefore there might be
a synergistic cytoprotective reaction, but as you quoted, amifostine
alone did not provide such renal protection.
DrRusch. I will close with a third question. Given the frequency
of intra-abdominal recurrence in this study and the well-known risk
of tumor implantation by mesothelioma, have you reconsidered
your strategy of perfusing both the chest and the abdomen?
Dr Tilleman. We reported in 1997 local recurrence within the
ipsilateral hemithorax and by direct extension into the abdomen.14
Adding intraoperative intracavitary chemotherapy reduced local re-
currences from 67% to 34%, yet the abdominal recurrences did not
change, even after adding intracavitary chemotherapy (Table 4).
Baldini and coworkers’ work14 showed the same abdominal
recurrence rate (50% recurrence). Therefore, yes, a more rigorous
treatment might be needed, including washing first the abdomen,
omentectomy, and administration of systemic chemotherapy. All
might reduce recurrences in the abdomen.Cardiovascular Surgery c Volume 138, Number 2 411
